Editor’s Note
**Editor’s Note:** Hugel has officially introduced its botulinum toxin Letybo to the Indian market at the Global Aesthetics Summit in Goa, targeting a 9% market share this year. The company’s push highlights growing competition in India’s aesthetics sector.
Hugel participated in the Global Aesthetics Summit (GAS) held at the Taj Horizon in Goa, India, from the 19th to the 21st, announcing the official entry of its botulinum toxin ‘Letybo’ into the Indian market. Hugel aims to achieve a 9% market share in the Indian aesthetics market this year, accelerating its early market penetration.
At the GAS conference, Hugel partnered with its local distributor Aakaar Medical to secure brand recognition and establish a Key Opinion Leader (KOL) network. Benjamin Chan, Hugel’s Australian KOL who served as a speaker, highlighted the product’s differentiation by introducing Letybo’s predictable treatment outcomes through ‘Narrow Diffusion’.
Hugel plans to sequentially conduct separate launch events and hands-on workshops with its local distributor until the 24th. The company also intends to continuously expand academic exchanges with KOLs to further strengthen Letybo’s position in the global market.